Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 15/20 | 0.37 |
| ▸ | SCN2B | O60939 | 2/20 | 0.36 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.35 |
| ▸ | SCN1A | P35498 | 3/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17048667 | 0.79 | SCN9A (0.50) | HSD11B1SCN9ASCN2BSCN1BSCN5A | |
| SCHEMBL17048644 | 0.78 | ALDH1A1 (0.45) | SCN9ASCN2BSCN1BSCN5ASCN1A | |
| SCHEMBL20238716 | 0.70 | SCN9A (0.59) | SCN9ASCN2BSCN1BSCN5ASCN1A | |
| SCHEMBL29669015 | 0.70 | SCN9A (0.59) | SCN9ASCN2BSCN1BSCN5ASCN1A | |
| SCHEMBL20449533 | 0.68 | SCN9A (0.54) | SCN9ASCN2BSCN1BSCN5ASCN1A | |
| SCHEMBL16177924 | 0.67 | SCN8A (0.53) | SCN9ASCN5ASCN1ASCN8ACYP3A4 | |
| SCHEMBL16177329 | 0.67 | SCN5A (0.59) | SCN9ASCN1BSCN5ASCN1ASCN8A | |
| SCHEMBL5399886 | 0.67 | MEP1B (0.43) | SCN9A | |
| SCHEMBL5831012 | 0.66 | HSD11B1 (0.70) | HSD11B1SCN1BSCN5ASCN1ASCN8A | |
| SCHEMBL18882723 | 0.66 | SCN9A (0.38) | SCN9ASCN2BSCN1BSCN5ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | DeGiacomo, Mark G. (US) | 2017-05-25 | — | — | US | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130957-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145003-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, SCN1A, CACNA1S | HSD11B1 2329/4885SCN9A 29/4885SCN2B 15/4885 |
| US-11236078-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPM6, SCN1A | HSD11B1 2682/4885SCN9A 32/4885SCN2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.